Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Anlotinib Hcl
2. 1360460-82-7
3. Anlotinib Hydrochloride
4. Al3818 Dihydrochloride
5. Catequentinib Hydrochloride
6. Catequentinib Dihydrochloride
7. A3749m6582
8. 1360460-82-7 (hcl)
9. 1-[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl]oxymethyl]cyclopropan-1-amine;dihydrochloride
10. Catequentinib Hydrochloride (usan)
11. Anlotinib 2hcl
12. 1-(((4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxyquinolin-7-yl)oxy)methyl)cyclopropan-1-amine Dihydrochloride
13. 1-[({4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxyquinolin-7-yl}oxy)methyl]cyclopropan-1-amine Dihydrochloride
14. Catequentinib Hydrochloride [usan]
15. 1-[[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-quinolinyl]oxy]methyl]cyclopropanamine Hydrochloride (1:2); Al3818 Dihydrochloride
16. Chembl5314570
17. Schembl18691323
18. Al-3818 Dihydrochloride
19. Unii-a3749m6582
20. Bcp19682
21. Anlotinib (al3818) Dihydrochloride
22. Hy-19716a
23. S8726
24. Ccg-269545
25. Catequentinib Hydrochloride [who-dd]
26. Cs-0040093
27. D12537
28. D72434
29. 1-((4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-quinolyl)oxymethyl)cyclopropanamine, Dihydrochloride
30. 1-[[[4-(4-fluoro-2-methyl-1h-indol-5-yloxy)-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropanamine Dihydrochloride
31. Cyclopropanamine, 1-(((4-((4-fluoro-2-methyl-1h-indol-5-yl)oxy)-6-methoxy-7-quinolinyl)oxy)methyl)-, Hydrochloride (1:2)
32. Cyclopropanamine, 1-[[[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-quinoliny]oxy]methyl]-, Hydrochloride (1:2)
1. 1058156-90-3
2. Anlotinib
| Molecular Weight | 480.4 g/mol |
|---|---|
| Molecular Formula | C23H24Cl2FN3O3 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 82.4 |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 606 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Drugs in Development
Details:
(TQB2868) is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Lead Product(s): TQB2868,Anlotinib Hydrochloride,Gemcitabine,Paclitaxel
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 10, 2025
Lead Product(s) : TQB2868,Anlotinib Hydrochloride,Gemcitabine,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : (TQB2868) is currently being evaluated in Phase III clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 10, 2025
Details:
Anlotinib HCl is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Sarcoma.
Lead Product(s): Anlotinib Hydrochloride,Bempegaldesleukin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Chia Tai Tianqing Pharmaceutical Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 05, 2025
Lead Product(s) : Anlotinib Hydrochloride,Bempegaldesleukin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Chia Tai Tianqing Pharmaceutical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Anlotinib HCl is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Sarcoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 05, 2025
Details:
Anlotinib Hydrochloride is a tyrosine kinase inhibitor which is indicated for the treatment of unresectable locally advanced or metastatic soft tissue sarcoma.
Lead Product(s): Anlotinib Hydrochloride,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2025
Lead Product(s) : Anlotinib Hydrochloride,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Approval Granted For Anlotinib Combo In Soft Tissue Sarcoma
Details : Anlotinib Hydrochloride is a tyrosine kinase inhibitor which is indicated for the treatment of unresectable locally advanced or metastatic soft tissue sarcoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2025
Details:
Realgar is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Ovarian Neoplasms.
Lead Product(s): Realgar,Indigo Naturalis,Anlotinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Vitamins/Minerals/Inorganic Salts
Sponsor: Beijing Friendship Hospital | Peking University First Hospital | The First Affiliated Hospital of Zhengzhou University | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Tianjin People’s Hospital | The First Affiliated Hospital of Shanxi
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 20, 2025
Lead Product(s) : Realgar,Indigo Naturalis,Anlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Beijing Friendship Hospital | Peking University First Hospital | The First Affiliated Hospital of Zhengzhou University | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Tianjin People’s Hospital | The First Affiliated Hospital of Shanxi
Deal Size : Inapplicable
Deal Type : Inapplicable
RIF + Anlotinib Safety & Efficacy In Advanced Recurrent Platinum-Resistant Ovarian Cancer
Details : Realgar is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
July 20, 2025
Details:
Benmelstobart is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Small Cell Lung Carcinoma.
Lead Product(s): Benmelstobart,Anlotinib Hydrochloride,Carboplatin,Cisplatin,Etoposide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Chia Tai Tianqing Pharmaceutical Group
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 17, 2025
Lead Product(s) : Benmelstobart,Anlotinib Hydrochloride,Carboplatin,Cisplatin,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Chia Tai Tianqing Pharmaceutical Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Benmelstobart is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 17, 2025
Details:
Carboplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Small Cell Lung Carcinoma.
Lead Product(s): Carboplatin,Cisplatin,Etoposide,Benmelstobart,Anlotinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Cytotoxic Drug
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2025
Lead Product(s) : Carboplatin,Cisplatin,Etoposide,Benmelstobart,Anlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Carboplatin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Small Cell Lung Carcinoma.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
March 27, 2025
Details:
TQB2868 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Lead Product(s): TQB2868,Gemcitabine,Paclitaxel,Anlotinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Undisclosed
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 10, 2025
Lead Product(s) : TQB2868,Gemcitabine,Paclitaxel,Anlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TQB2868 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 10, 2025
Details:
AK105 (penpulimab) is a differentiated PD-1 monoclonal antibody, which is being evaluated in combination with Anlotinib HCl for the first-line (1L) treatment of advanced hepatocellular carcinoma.
Lead Product(s): Penpulimab,Anlotinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 22, 2024
Lead Product(s) : Penpulimab,Anlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Akeso’s Penpulimab Combo for Hepatocellular Cancer Accepted by NMPA in China
Details : AK105 (penpulimab) is a differentiated PD-1 monoclonal antibody, which is being evaluated in combination with Anlotinib HCl for the first-line (1L) treatment of advanced hepatocellular carcinoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
November 22, 2024
Details:
HS-20093 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteosarcoma.
Lead Product(s): HS-20093,Anlotinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody-drug Conjugate
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2024
Lead Product(s) : HS-20093,Anlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HS-20093 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Osteosarcoma.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
November 21, 2024
Details:
Nab-Paclitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Biliary Tract Neoplasms.
Lead Product(s): Paclitaxel,Tegafur,Gimeracil,Oteracil,Anlotinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Cytotoxic Drug
Sponsor: CTTQ Pharma
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 29, 2024
Lead Product(s) : Paclitaxel,Tegafur,Gimeracil,Oteracil,Anlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : CTTQ Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nab-Paclitaxel is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Biliary Tract Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 29, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
70
PharmaCompass offers a list of Anlotinib Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Anlotinib Hydrochloride manufacturer or Anlotinib Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Anlotinib Hydrochloride manufacturer or Anlotinib Hydrochloride supplier.
PharmaCompass also assists you with knowing the Anlotinib Hydrochloride API Price utilized in the formulation of products. Anlotinib Hydrochloride API Price is not always fixed or binding as the Anlotinib Hydrochloride Price is obtained through a variety of data sources. The Anlotinib Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Anlotinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Anlotinib, including repackagers and relabelers. The FDA regulates Anlotinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Anlotinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Anlotinib supplier is an individual or a company that provides Anlotinib active pharmaceutical ingredient (API) or Anlotinib finished formulations upon request. The Anlotinib suppliers may include Anlotinib API manufacturers, exporters, distributors and traders.
click here to find a list of Anlotinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Anlotinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Anlotinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Anlotinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Anlotinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Anlotinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Anlotinib suppliers with NDC on PharmaCompass.
Anlotinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Anlotinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Anlotinib GMP manufacturer or Anlotinib GMP API supplier for your needs.
A Anlotinib CoA (Certificate of Analysis) is a formal document that attests to Anlotinib's compliance with Anlotinib specifications and serves as a tool for batch-level quality control.
Anlotinib CoA mostly includes findings from lab analyses of a specific batch. For each Anlotinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Anlotinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Anlotinib EP), Anlotinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Anlotinib USP).
